Roxro Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
Dr. Neil Singla, Chief Executive Officer of Lotus Clinical Development, Inc. and lead investigator for ROXRO’s second Phase 3 study said “ROX-888 could fulfill a compelling medical need for both clinicians and patients”
